Skip to main content

Basic Science: Prejunctional and Presynaptic Trigeminovascular Targets: What Preclinical Evidence Is There?

Buy Article:

$51.00 plus tax (Refund Policy)


Inhibition of trigeminovascular nociceptive traffic by a prejunctional/presynaptic mechanism is an attractive approach for the treatment of migraine. It has been shown that blocking the presumed postsynaptic actions of calcitonin gene-related peptide (CGRP) is an effective acute antimigraine strategy, so that blockade of CGRP release by presynaptic inhibition also seems promising. A number of targets are reviewed including serotonin 5-HT1F and 5-HT1D receptor agonists, adenosine A1 receptor agonists, nociceptin, and vanilloid VR1 receptors. For each, the preclinical rationale for their involvement in prejunctional/presynaptic mechanisms is reviewed. Development of one or more such compounds offers the exciting prospect of new nonvasoconstrictor treatments for migraine and cluster headache.

Document Type: Research Article


Publication date: 2004-07-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more